TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report published on Friday. The firm issued a hold rating on the stock.

TherapeuticsMD Trading Down 1.6 %

Shares of NASDAQ TXMD opened at $1.86 on Friday. TherapeuticsMD has a 12-month low of $1.86 and a 12-month high of $4.73. The stock has a fifty day moving average price of $2.26 and a 200 day moving average price of $2.33.

Institutional Trading of TherapeuticsMD

Several large investors have recently added to or reduced their stakes in TXMD. State Street Corp grew its stake in shares of TherapeuticsMD by 13.6% during the first quarter. State Street Corp now owns 30,130 shares of the company’s stock valued at $113,000 after acquiring an additional 3,600 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of TherapeuticsMD by 6.3% during the first quarter. Principal Financial Group Inc. now owns 123,319 shares of the company’s stock valued at $47,000 after acquiring an additional 7,263 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of TherapeuticsMD by 18.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 52,521 shares of the company’s stock valued at $197,000 after acquiring an additional 8,064 shares in the last quarter. UBS Group AG grew its stake in shares of TherapeuticsMD by 258.1% during the second quarter. UBS Group AG now owns 18,133 shares of the company’s stock valued at $180,000 after acquiring an additional 13,069 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of TherapeuticsMD by 4.8% during the first quarter. Rhumbline Advisers now owns 312,526 shares of the company’s stock valued at $119,000 after acquiring an additional 14,372 shares in the last quarter. 30.74% of the stock is currently owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.